Leading community-based practice to utilize increased set of solid tumor applications
SOPHiA GENETICS Announces Expanded Partnership with Tennessee Oncology
read more
Christophe Pignol
SOPHiA GENETICS Launches MSK-IMPACT® powered with SOPHiA DDM™ at AMP 2024
Launch of new application enables global access to high-performing solid tumor profiling assay
Advancing precision oncology with MSK-ACCESS® powered with SOPHiA DDM™ – ELBS & SOPHiA GENETICS webinar (European Liquid Biopsy Society)
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader...
SOPHiA GENETICS and Genomenon Collaborate to Streamline Genetic Research
BOSTON and ROLLE, Switzerland, November 6, 2024 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native...
SOPHiA GENETICS Promotes Ross Muken to President and Appoints George Cardoza as Chief Financial Officer
BOSTON, United States and ROLLE, Switzerland, November 5, 2024 — SOPHiA GENETICS (Nasdaq: SOPH), a...
SOPHiA GENETICS Reports Third Quarter 2024 Results
Clinical growth reaccelerates with record analysis volume; Cash burn improves 39% BOSTON and...
ECP Posters spotlight
We recently presented two posters at the European Congress of Pathology 2024, in Florence, Italy,...
BioJapan Congress 2024
SOPHiA GENETICS™ is excited to be for the first time part of the BioJapan Congress. You will have...
SOPHiA DDM™ Platform Certified Under IVDR
Regulatory milestone validates the SOPHiA DDM™ Platform as diagnostic tool in select markets.
Enhancing variant interpretation: Obtaining answers from a vast universe of data
Pinpointing pathogenic mutations from large, complex datasets can be difficult, time-consuming,...
Case Study: Unlocking access to MSK-ACCESS® for robust liquid biopsy analysis
Memorial Sloan Kettering Cancer Center (MSK) is a world leading institution for cancer treatment and research. We’re collaborating with MSK to expand access to precision cancer analysis capabilities worldwide.
SOPHiA GENETICS Reports Second Quarter 2024 Results
Strength in U.S. Growth Offset by Challenges in BioPharma and EMEA; Strong Cost Management Buffers Loss